Jean Grem, M.D.
Professor, Internal Medicine
Division of Oncology & Hematology
Academic office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 681980-6840
Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
Fred & Pamela Buffett Cancer Center
505 South 45th Street
Omaha, NE 68105 (map)
Nebraska Medicine Village Pointe
111 North 175th Street
Omaha, NE 68118 (map)
1972-1976 Purdue University, Biology
1976-1980 Jefferson Medical College, Medicine
1980-1983 University of Iowa Hospitals & Clinics, Internal Medicine
1983-1986 University of Wisconsin Clinical Cancer Center, Medical Oncology
Gastrointestinal Cancers and Neuroendocrine (Carcinoid Tumors)
Dr. Grem is Professor of Medicine and joined UNMC in 2003. Prior to joining UNMC, Dr. Grem was Senior Investigator at the National Cancer Institute, in Bethesda, Maryland since 1986. She became the Head of the Gastrointestinal Malignancies Division, Cancer Therapeutics Branch at the National Cancer Institute in 2001. Dr. Grem is known nationally as an expert in gastrointestinal malignancies and is currently exploring several novel therapeutic approaches in both colon and pancreatic cancer at UNMC. Dr. Grem is currently the Associate Director for Translational Research of the UNMC Eppley Cancer Center. Dr. Grem has published over 110 peer-reviewed articles in various cancer-related medical journals. Dr. Grem reviews for various oncology and basic science journals and has been invited to review grant application in various funding agencies.
William BM, Grem JL, Brain metastasis and leptomeningeal carcinomatosis in a patient with cholangiocarcinoma. Gastroint Cancer Res 4:144-5, 2011.
Benson AB 3rd,Bekaii-Saab,T, Chan E, Chen YJ, Choti, MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs C, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous C, Venook AP, Willet C, Gregory KM, Freedman-Cass DA, Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 11:519-28, 2013.
Mansky PJ, WSallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, Grem JL, Swain SM, Monahan BP, NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evidence-Based Complementary and Alternative Medicine Volume 2013: pp.964592
Grem JL, Sequencing of treatment in advanced unresectable colorectal cancer. J Natl Compr Canc Netw 11 Suppl 4, pp.S28-37, 2013.
Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kame A Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Feedman-Cass DA. Colon cancer, version 3.2014. J Natl Compr Cnc Netw 12: 1028-59, 2014
Kattel K, Evande RE, Tan C, Mondal G, Gream JL , Mahato RI, Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in pancreatic cancer patients. Br J Clin Pharmacol, ISSN: 1365-2125, 2015 Mar 5; Publisher: Wiley-Blackwell; PMID: 25752914.
Borad MJ, Babiker HM, Anthony S, MIta M, Buchbinder A, Keilani T, Grem J. A multicenter, open-label, phase 1 study evaluation the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma. Cancer Invest ISSN: 1532-4192, 2015 Apr 6;Publisher: Informa Healthcare; PMID: 25844818
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed